The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)
WPD Pharmaceuticals’ Licensor CNS Pharmaceuticals Receives FDA Fast Track Designation For Berubicin For The Treatment Of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. ("CNS")
CNS Pharma Reports Corporate Update
Recently launched potentially pivotal study for lead program evaluating Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), with patient dosing expected to commence in Q3 2021
Continued execution on
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin
CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM).…